ASPREE-XT is a post-treatment, longitudinal observational follow-up study of ASPREE
participants [ASPREE Investigator Group, 2013; www.aspree.org; McNeil et al 2017]. Although
the ASPREE trial medication was ceased, the study activity was not stopped and ASPREE
participants are continuing with scheduled visits and phone calls. An observational follow-up
phase (ASPREE-XT), began in January, 2018. This will enable the monitoring of possible
delayed effects of aspirin treatment, primarily on cancer incidence, metastases and
mortality. In addition to monitoring the incidence of malignancy within the ASPREE cohort,
the opportunity will be taken to observe any other residual effects of aspirin on the
endpoints being monitored in the cohort. Continuity of contact with study participants is the
key to retention of the cohort for any ongoing or future studies.
Details
Lead Sponsor:
Hennepin Healthcare Research Institute Minneapolis Medical Research Foundation
Collaborators:
Bayer Berman Center for Outcomes and Clinical Research Monash University National Cancer Institute (NCI) National Health and Medical Research Council, Australia National Institute on Aging (NIA)